



Research Article

Therapeutic evaluation of galangin on cartilage protection and analgesic activity in a rat model of osteoarthritis

Yan Su^{a,1}, Longxiang Shen^{a,1}, Jianfeng Xue^a, Jian Zou^a, Daqian Wan^{b,c,*}, Zhongmin Shi^{a,*}^a Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, No. 600, YiShan Road, Shanghai 200233, People's Republic of China^b Department of Orthopedics, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, People's Republic of China^c Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration, Ministry of Education of the People's Republic of China, Shanghai, People's Republic of China

ARTICLE INFO

Article history:

Received 29 September 2020

Accepted 25 May 2021

Available online xxxx

Keywords:

Analgesic
Antioxidant
Arthritis
Cartilage
Galangin
Osteoarthritis
Protection
Rats
Therapeutic evaluation
Type II collagen

ABSTRACT

Background: Osteoarthritis (OA) is a form of arthritis due to degradation of articular cartilage. OA is associated with stiffness, joint pain, and dysfunction, affecting adults worldwide. Galangin is a bioactive flavonoid that exerts several therapeutic and biological activities. Anti-hyperglycemic, anti-inflammatory, anti-cancer, and anti-apoptotic activities of galangin have been reported in several studies. In the present study, rats were divided into normal control, OA (control), galangin 10 mg/kg (low-dose), galangin 100 mg/kg (high-dose), and celecoxib 30 mg/kg (positive control) groups. All doses were administered orally for 14 consecutive days. The urinary type II collagen (μ CTX-II) level as well as reactive oxygen species, tumor necrosis factor- α , interleukin-1 beta, interleukin-6, superoxide dismutase, catalase, lipid peroxidation, reduced glutathione, and glutathione peroxidase levels were measured. In addition, the CTX-II mRNA and protein expression levels were measured.

Results: Galangin supplementation significantly reduced the μ CTX-II level compared with controls. Galangin treatment significantly reduced reactive oxygen species, lipid peroxidation, interleukin-1 beta, interleukin-6, and tumor necrosis factor- α levels, but increased catalase, superoxide dismutase, glutathione peroxidase, and reduced glutathione levels. Galangin treatment significantly reduced the CTX-II mRNA and protein expression levels. The low CTX-II level in tissue indicated the inhibition of cartilage degradation.

Conclusions: In summary, supplementation with galangin was effective against OA. The identification of potential therapeutic agents that inhibit inflammation may be useful for the management and prevention of OA.

How to cite: Su Y, Shen L, Xue J, et al. Therapeutic evaluation of galangin on cartilage protection and analgesic activity in a rat model of osteoarthritis. *Electron J Biotechnol* 2021;52. <https://doi.org/10.1016/j.ejbt.2021.05.005>

© 2021 Pontificia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Osteoarthritis (OA) is a form of arthritis due to degradation of articular cartilage [1]. OA is associated with stiffness, joint pain, and dysfunction, affecting adults worldwide [2]. Allen et al. [3] reported that joint injury, genetic factors, and development of abnormal limb are the main causes of OA. Symptoms usually develop gradually and affect the activities of daily living [4]. Researchers have reported that mechanical stress and inflamma-

tion (low-grade) induce OA [5]. McAlindon et al. [6] reported that regular exercise and pain medications are helpful for the treatment of OA. Although several advances have been made in drug discovery for the treatment of OA, successful therapies and drugs are not yet available [7]. In the present study, whether symptomatic relief could inhibit the primary etiology that causes the severe articular structure damage in OA was investigated.

Plants, food, and beverages act as potential biological and therapeutic agents in traditional and modern clinical treatments [8]. Natural flavonoids are widely present in several plants and known to exert various therapeutic activities such as anti-cancer, anti-diabetic, anti-hypertensive, and anti-hepatotoxic effects [9,10,11,12,13]. Galangin is a bioactive flavonoid possessing several therapeutic and biological properties [14]. Several researchers

Peer review under responsibility of Pontificia Universidad Católica de Valparaíso

* Corresponding authors.

E-mail addresses: zpowza@163.com (D. Wan), zhongmin143@gmail.com (Z. Shi).¹ These authors contribute to this work equally.<https://doi.org/10.1016/j.ejbt.2021.05.005>

0717-3458/© 2021 Pontificia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

have reported anti-hyperglycemic, anti-inflammatory, anti-cancer, and anti-apoptotic activities of galangin [15,16,17]. Fang et al. [18] have reported the chemopreventive effect of galangin against hepatocellular carcinoma. Huang et al. [19] have reported the anti-cancer activity of galangin through p53-dependent pathway in ovarian cancer. Xuan et al. [20] have reported the protective effect of galangin against acute colitis through the modulating gut microbiota and activating autophagy. Aladaileh et al. [14] have reported the therapeutic effect of galangin against oxidative damage and apoptosis in hepatotoxicity induced rats. Researchers have reported the effect of galangin on the mRNA expression and activities of seven CYP450, and DPP-4 inhibitory effect of galangin, and improves glucose uptake in skeletal muscles [21,22]. Patil et al. [23] have reported the effect of galangin loaded galactosylated pluronic F68 polymeric micelles for liver targeting. Yang et al. [24] have reported the inhibitory effect of galangin against MMP-9 expression in SK-N-SH cells. Sulaiman [25] have reported the anti-proliferative effect of galangin in HCT-116 cells. Kale and Namdeo [26] reported the anti-arthritis activity of galangin in arthritis-induced rats. Fu et al. [27] reported the protective effects of galangin against human rheumatoid arthritis via downregulation of the NF- κ B/NLRP3 pathway. Thus, in the present study, the therapeutic effects of galangin against OA were analyzed in Sprague-Dawley rats.

2. Materials and methods

2.1. Rats

Sprague-Dawley rats (190–210 g) were obtained from the animal house of Shanghai Jiao Tong University Affiliated Sixth People's Hospital (No. 600, YiShan Road, Shanghai 200233, People's Republic of China). All rats were kept in polycarbonate cages under 12-h light/12-h dark and standard atmospheric conditions. All rats had free access to food and water. Each experiment was performed following the guidelines for the care and use of laboratory animals and institutional guidelines.

2.2. Induction of OA

Monoiodoacetate (MIA) was used for the induction of OA. Briefly, the rats were anesthetized with isoflurane and 3 mg/kg of MIA in 50 μ L normal saline was injected into the intra-articular pocket of the left femorotibial joint using a 26 G needle. All rats were carefully monitored daily for abnormal swelling and OA was established 7 d after MIA injection [7].

2.3. Experimental groups

The 30 male rats were randomly divided into five groups: normal control (NC), OA (control), galangin 10 mg/kg (low-dose), galangin 100 mg/kg (high-dose), and celecoxib 30 mg/kg (positive control). The doses were administered orally for 14 consecutive days. Each group contained six rats.

2.4. Enzyme-linked immunosorbent assay (ELISA)

The urinary type II collagen (μ CTX-II) levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol. Briefly, the rat urine was collected, kept on ice, and diluted at a 1:3 ratio using sample diluent. Then, 100 μ L of standards and samples were added to CTX-II antibody pre-coated 96-well plates and incubated for 120 min at room temperature. Next, 100 μ L of detection reagent was added to all wells and incubated for 60 min. Then, the solution

was discarded, and samples were incubated with blocking solution for 60 min. Next, wells were incubated with substrate for 30 min followed by addition of 50 μ L stop solution; absorbance was measured at 450 nm [7].

2.5. Biomarkers

At the end of the treatment, femorotibial joints were carefully dissected, homogenized, centrifuged, and supernatant collected. Reactive oxygen species (ROS), tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and IL-6 levels were measured in the supernatant [28]. In addition, superoxide dismutase (SOD), catalase, lipid peroxidation, reduced glutathione (GSH), and glutathione peroxidase (Gpx) levels were measured in the supernatant [28].

2.6. RT-PCR

Total RNA was extracted from femorotibial joint tissues and converted into cDNA using oligo(dT) primers. The qPCR was used to measure mRNA expression with specific primers for CTX-II (forward: 5-CGGGCRATGGCGCARAC-3; reverse: 5-TGCRCCGTS GTATTGCC-3). The $2^{-\Delta\Delta CT}$ method was used to quantitate the relative expression of CTX-II [29].

2.7. Western blot analysis

The proteins in the femorotibial joint tissue homogenate were separated using SDS-PAGE and then transferred to PVDF membranes. Membranes were treated with CTX-II primary antibodies (ab34712, Abcam, Cambridge, MA, USA) overnight. Then, membranes were washed and treated with horseradish peroxidase (HRP)-IgG (ab97023, Abcam) for 60 min. Finally, the CTX-II protein level was measured using a standard method [30].

2.8. Immunohistochemistry

At the end of the treatment, femorotibial joints were carefully dissected and sliced into thin sections. Then, tissue sections were incubated with CTX-II primary antibodies (ab34712, Abcam) overnight. Next, sections were treated with horseradish peroxidase (HRP)-IgG (ab97023, Abcam) for 60 min. The sections were viewed under a fluorescence microscope [31].

2.9. Statistical analysis

The values are presented as the means \pm standard error of the mean. The differences between the control and galangin-treated groups were evaluated using Student's *t*-test and analysis of variance. A *P*-value <0.05 was considered statistically significant.

3. Results

In the present study, the therapeutic effects of galangin on OA were analyzed in Sprague-Dawley rats. The progression of articular cartilage degradation directly correlated with μ CTX-II level, a type II collagen. The μ CTX-II level drastically increased 79% in OA rats due to degradation of articular cartilage. However, the μ CTX-II level was significantly reduced by 5.7% and 35.9% after 14 consecutive days of treatment with 10 mg/kg and 100 mg/kg galangin, respectively (Table 1, *P* < 0.05). The μ CTX-II was significantly reduced (39.1%) after 14 consecutive days of treatment with celecoxib, positive control drug (Table 1, *P* < 0.05). The low μ CTX-II level indicated the inhibition of cartilage degradation and protective effect of galangin against OA.

Table 1
The urine CTX-II (uCTX-II) normalized to total protein at 14 d.

Group	uCTX-II (ng/l)	Total protein (g/l)	Ratio (CTX-II/protein)
Normal control	362 ± 23	3.41 ± 0.25	106.2
OA	648 ± 27 [#]	6.75 ± 0.46 [#]	96
Galangin (10 mg/kg)	611 ± 21	7.13 ± 0.51	85.7
Galangin (100 mg/kg)	415 ± 29*	7.25 ± 0.34*	57.2
Celecoxib (30 mg/kg)	394 ± 26*	4.41 ± 0.25*	89.3

[#]*P* < 0.05 vs. Normal control; **P* < 0.05 vs. OA.

ROS from osteoblasts, synoviocytes and chondrocytes activates the cartilage degradation due to ruptured joint homeostasis which favors catabolic processes. The intracellular ROS level was expressed as relative fluorescence units (RFUs). Compared with the OA group, the galangin supplementation significantly reduced the ROS level by 9.9% and 40.7% at 10 mg/kg and 100 mg/kg galangin, respectively (Fig. 1, *P* < 0.05). Intracellular ROS level was significantly reduced (47.4%) after 14 consecutive days of treatment with celecoxib (Fig. 1, *P* < 0.05). Pro-inflammatory mediators such as cytokines and lipid mediators from osteoblasts, synoviocytes and chondrocytes activates the cartilage degradation due to ruptured joint homeostasis which favors catabolic processes. Inflammatory markers were significantly increased in OA rats compared with the normal controls. However, the galangin supplementation significantly reduced IL-1β, IL-6, and TNF-α levels after 14 consecutive days of treatment (Fig. 2, *P* < 0.05). In addition, IL-1β, IL-6, and TNF-α levels were reduced after 14 consecutive days of treatment with celecoxib (Fig. 2, *P* < 0.05).

The imbalance and disturbance of pro-oxidant/anti-oxidant leads to oxidative stress, which can be corrected through the addition of appropriate anti-oxidants. Compared with controls, the galangin supplementation increased the catalase, SOD, Gpx, and GSH levels after 14 consecutive days of treatment (Table 2, *P* < 0.05). The celecoxib supplementation also increased catalase, SOD, Gpx and GSH levels after 14 consecutive days of treatment (*P* < 0.05, Table 2). Excessive lipid peroxidation is thought to have an important role in the pathogenesis of OA. Lipid peroxidation was significantly increased in the OA rats. However, the galangin supplementation significantly reduced lipid peroxidation to near normal range after 14 consecutive days of treatment (Table 2, *P* < 0.05).




Fig. 1. Protective effects of galangin on intracellular reactive oxygen species (ROS) level in osteoarthritis (OA) rat model. [#]*P* < 0.05 vs. Normal control; **P* < 0.05 vs. Control (OA); *N* = 6.

The progression of articular cartilage degradation directly correlated with CTX-II level. The CTX-II mRNA and protein expression levels were measured. The CTX-II mRNA expression was significantly increased by 80% in the OA rats. However, 10 mg/kg and 100 mg/kg galangin supplementation significantly reduced OA in rats by 8.3% and 23.9%, respectively (Fig. 3A, *P* < 0.05). The celecoxib supplementation significantly reduced the CTX-II mRNA expression by 27.8% after 14 consecutive days of treatment (Fig. 3A, *P* < 0.05). CTX-II protein expression was increased by 70% in the OA rats. However, 10 mg/kg and 100 mg/kg galangin supplementation significantly reduced OA in rats by 5.3% and 17.1%, respectively (Fig. 3B-C, *P* < 0.05). The celecoxib supplementation also significantly reduced the CTX-II protein expression by 19.4% after 14 consecutive days of treatment (Fig. 3B-C, *P* < 0.05). Immunohistochemistry results showed the CTX-II protein expression was significantly increased by 65% in the OA rats. However, 10 mg/kg and 100 mg/kg galangin supplementation significantly reduced OA in rats by 7.3% and 18.2%, respectively (Fig. 4A-B, *P* < 0.05). The celecoxib supplementation also significantly reduced the CTX-II protein expression by 17.6% after 14 consecutive days of treatment (Fig. 4A-B, *P* < 0.05). The low CTX-II level in tissue indicates the inhibition of cartilage degradation and protective effect of galangin against OA.

4. Discussion

In the present study, the therapeutic effects of galangin on OA were analyzed in Sprague-Dawley rats. OA is a form of arthritis due to the degradation of articular cartilage [1]. Allen et al. [3] reported that joint injury, genetic factors, and development of abnormal limb are the main causes of OA. The symptoms usually develop gradually and affect the activities of daily living [4]. Researchers have reported that mechanical stress and inflammation (low-grade) induce OA [5]. McAlindon et al. [6] reported that regular exercise and pain medications are helpful for treatment of OA. Although several advances have been made in drug discovery for the treatment of OA, successful therapies and drugs are not yet available [7].

OA model induction was confirmed based on increased CTX-II level and hypersensitivity, as well as histopathology results (data not shown). The results confirmed the significant improvement in pain tolerance and protection of articular cartilage. In addition,




Fig. 2. Protective effects of galangin on tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and IL-6 levels in osteoarthritis (OA) rat model. [#]*P* < 0.05 vs. Normal control; ^{*}*P* < 0.05 vs. Control (OA); *N* = 6.

Table 2
Protective effect of galangin on antioxidant markers in monoiodoacetate (MIA) induced OA model rats.

Markers	Normal control	OA	Galangin (10 mg/kg)	Galangin (100 mg/kg)	Celecoxib (30 mg/kg)
Catalase (U/ml)	10.9 ± 0.2	4.2 ± 0.2 [#]	6.1 ± 0.2 [*]	8.5 ± 0.3 [*]	9.3 ± 0.3 [*]
SOD (U/ml)	361.5 ± 13	138 ± 11 [#]	193 ± 15 [*]	272 ± 17 [*]	296 ± 16 [*]
GSH (nmol/ml)	0.55 ± 0.03	0.21 ± 0.01 [#]	0.27 ± 0.04 [*]	0.42 ± 0.05 [*]	0.45 ± 0.05 [*]
Gpx (U/ml)	0.43 ± 0.03	0.24 ± 0.01 [#]	0.32 ± 0.01 [*]	0.38 ± 0.01 [*]	0.41 ± 0.01 [*]
MDA (nmol/ml)	0.58 ± 0.02	1.18 ± 0.1 [#]	0.91 ± 0.03 [*]	0.73 ± 0.05 [*]	0.68 ± 0.05 [*]

[#]*P* < 0.05 vs. Normal control; ^{*}*P* < 0.05 vs. OA.




Fig. 3. Protective effects of galangin on CTX-II mRNA and protein expression levels in osteoarthritis (OA) rat model. A. CTX-II mRNA expression. B and C. CTX-II protein expression. [#]*P* < 0.05 vs. Normal control; ^{*}*P* < 0.05 vs. Control (OA); *N* = 6.

pain sensitivity was significantly inhibited after galangin treatment. The μCTX-II level was significantly reduced after galangin treatment, indicating galangin exerted protective effects on articular cartilage confirming the merit of galangin as an analgesic and anti-inflammatory product. Castrogiovanni et al. [32] have reported the nutraceutical supplements in the Management and Prevention of OA through the reduction of CTX-II level. Dimitra

et al. [33] have reported that the flavonoids reduced CTX-II level in inflammatory arthritis.

Researchers have reported that inflammatory mediators including NF-κB, IL-1β, and IL-6 play key roles in OA [34]. Infiltration of macrophages, chronic inflammation, and activated T cells in joint tissues are the major pathological findings in arthritis [35]. Low levels of cellular antioxidants and increased free radical production




Fig. 4. Protective effects of galangin on CTX-II protein expression in osteoarthritis (OA) rat model based on immunohistochemistry. A. The immunohistochemical images of CTX-II. B. The relative CTX-II protein expression. [#]P < 0.05 vs. Normal control; ^{*}P < 0.05 vs. Control (OA); N = 6.

in inflamed areas aggravate arthritis [36]. Oxidation of membrane fatty acids and other chain reactions can lead to cell membrane damage [37]. Gonzalez-Gay et al. [38] reported that IL-1 β , IL-6, and TNF- α are arthritis markers. Goldring and Gravalles [39] reported that IL-1 and TNF- α are produced from synovium lining cells and chondrocytes of affected joints. Supplementation with galangin significantly inhibited these inflammatory markers. Leyva-López et al. [40] have reported that the flavonoids are vital modulators of pro-inflammatory cytokines, such as IL-1 β , IL-6 and TNF- α . Kaempferol is one of the important flavonoid known to have anti-inflammatory effect via suppressing IL-1 β , IL-6 and TNF- α levels in SW982 cells [41].

Researchers reported the MIA-induced rat model of OA is a frequently used standard model to mimic human OA [42]. The induction of OA involves the injection of MIA in the femorotibial joint area, which induces cartilage degradation and pain responses in the ipsilateral limb. Researchers have reported the MIA injection in the femorotibial joint area causes the disruption of chondrocyte glycolysis via inhibition of glyceraldehyde-3-phosphatase dehydrogenase, which leads to neovascularization, chondrocyte death, and inflammation [43]. Based on these pathological features, the MIA-induced rat model of OA is very useful for the investigation of anti-inflammatory and analgesic activities. The imbalance and disturbance of pro-oxidant/anti-oxidant leads to oxidative stress, which can be corrected through the addition of appropriate antioxidants. In this study, the galangin supplementation increased the catalase, SOD, Gpx, and GSH levels after 14 consecutive days of treatment. Researchers have reported that the kaempferol is known to have anti-oxidant effect via increasing catalase, SOD, Gpx, and GSH levels in SW982 cells [41]. Amal et al. [44] have reported that the galangin improves the anti-oxidant levels in diabetic rats.

Several researchers have reported the anti-hyperglycemic, anti-inflammatory, anti-cancer, and anti-apoptotic activities of galangin [15,16,17]. Kale et al. [26] reported the anti-arthritis activity of galangin in arthritis-induced rats. Fu et al. yy[27] reported the protective effects of galangin against human rheumatoid arthritis via downregulation of the NF- κ B/NLRP3 pathway. CTX-II in tissue was significantly reduced after galangin treatment, indicating that galangin exerted protective effects on articular cartilage and confirming that galangin is an analgesic and anti-inflammatory product.

5. Conclusions

Galangin supplementation significantly reduced the μ CTX-II level compared with controls. Galangin treatment significantly reduced ROS, lipid peroxidation, IL-1 β , IL-6, and TNF- α levels, but increased catalase, SOD, Gpx, and GSH levels. Galangin treatment significantly reduced the CTX-II mRNA and protein expression levels. In summary, supplementation with galangin was effective against OA. The identification of potential therapeutic agents that inhibit inflammation may manage and prevent OA.

Ethical statement

The study protocol was approved by the Ethics Committee of Tongji University School of Medicine, with the approval number (2019090/20-21).

Conflict of interest

All authors declare that they have no conflicts of interest.

Financial support

This study was supported by National Natural Science Foundation of China (No: 30901520), National Key Research and Development Program of the Ministry of Science and Technology of China (No: 2018YFC2001500), and China Postdoctoral Science Foundation (No: 2019M661633).

References

- [1] Lee YM, Son E, Kim SH, et al. Effect of *Alpinia oxyphylla* extract in vitro and in a monosodium iodoacetate-induced osteoarthritis rat model. *Phytomedicine* 2019;65. <https://doi.org/10.1016/j.phymed.2019.153095>.
- [2] Cisternas MG, Murphy L, Sacks JJ, et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. *Arthritis Care Res* 2016;68:574–80. <https://doi.org/10.1002/acr.22721> PMID: 26315529.
- [3] Allen J, Imbert I, Havelin J, et al. Effects of treadmill exercise on advanced osteoarthritis pain in rats. *Arthritis Rheumatol* 2017;69:1407–17. <https://doi.org/10.1002/art.40101> PMID: 28320059.
- [4] Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. *Lancet* 2015;386:376–87. [https://doi.org/10.1016/S0140-6736\(14\)60802-3](https://doi.org/10.1016/S0140-6736(14)60802-3).

- [5] Berenbaum F. Osteoarthritis as inflammatory disease (osteoarthritis is not osteoarthrosis!) *Osteoarthritis and Cartilage*. 2013; 21: 16-21. <https://doi.org/10.1016/j.joca.2012.11.012> PMID: 23194896.
- [6] McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 2014;22:363–88. <https://doi.org/10.1016/j.joca.2014.01.003> PMID: 24462672.
- [7] Yimam M, Horm T, Wright L. Cartilage protection and analgesic activity of a botanical composition comprised of *Morus alba*, *Scutellaria baicalensis*, and *Acacia catechu*. *Evid Based Complement Alternat Med* 2017;2017:7059068. <https://doi.org/10.1155/2017/7059068> PMID: 28904559.
- [8] Cowan MM. Plant products as antimicrobial agents. *Clin Microbiol Rev* 1999;12:564–82. <https://doi.org/10.1128/CMR.12.4.564> PMID: 10515903.
- [9] Tiwari BK, Kumar D, Abidi AB, et al. Efficacy of composite extract from leaves and fruits of medicinal plants used in traditional diabetic therapy against oxidative stress in alloxan-induced diabetic rats. *ISRN Pharmacol* 2014;2014. <https://doi.org/10.1155/2014/608590> PMID: 24729889.
- [10] Michael HN, Salib JY, Eskander EF. Bioactivity of diosmetin glycosides isolated from the epicarp of date fruits, *Phoenix dactylifera*, on the biochemical profile of alloxan diabetic male rats. *Phytother Res* 2013;27:699–704. <https://doi.org/10.1002/ptr.4777> PMID: 22761049.
- [11] Duarte J, Pérez-Palencia R, Vargas F, et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. *Br J Pharmacol* 2001;133:117–24. <https://doi.org/10.1038/sj.bjp.0704064> PMID: 11325801.
- [12] Su CH, Kuo CL, Lu KW, et al. Fisetin-induced apoptosis of human oral cancer SCC-4 cells through reactive oxygen species production, endoplasmic reticulum stress, caspase-, and mitochondria-dependent signaling pathways. *Environ Toxicol* 2017;32(6):1725–41. <https://doi.org/10.1002/tox.22396> PMID: 28181380.
- [13] Akachi T, Shiina Y, Ohishi Y, et al. Hepatoprotective effects of flavonoids from shekwasha (*Citrus depressa*) against D-galactosamine-induced liver injury in rats. *J Nutr Sci Vitaminol* 2010;56(1):60–7. <https://doi.org/10.3177/jnsv.56.60> PMID: 20354348.
- [14] Aladaileh SH, Abukhalil MH, Saghir SAM, et al. Galangin Activates Nrf2 signaling and attenuates oxidative damage, inflammation, and apoptosis in a rat model of cyclophosphamide-induced hepatotoxicity. *Biomolecules* 2019;9(8):346. <https://doi.org/10.3390/biom9080346> PMID: 31387329.
- [15] Aloud A, Veeramani C, Govindasamy C, et al. Galangin, a dietary flavonoid, improves antioxidant status and reduces hyperglycemia-mediated oxidative stress in streptozotocin-induced diabetic rats. *Redox Rep* 2017;22:290–300. <https://doi.org/10.1080/13510002.2016.1273437> PMID: 28030991.
- [16] Jung YC, Kim ME, Yoon JH, et al. Antiinflammatory effects of galangin on lipopolysaccharide-activated macrophages via ERK and NF- κ B pathway regulation. *Immunopharmacol Immunotoxicol* 2014;36:426–32. <https://doi.org/10.3109/08923973.2014.968257> PMID: 25270721.
- [17] Sivakumar AS, Anuradha CV. Effect of galangin supplementation on oxidative damage and inflammatory changes in fructose-fed rat liver. *Chem Biol Interact* 2011;193:141–8. <https://doi.org/10.1016/j.cbi.2011.06.003> PMID: 21708140.
- [18] Fang D, Xiong Z, Xu J, et al. Chemopreventive mechanisms of galangin against hepatocellular carcinoma: A review. *Biomed Pharmacother* 2019;109:2054–61. <https://doi.org/10.1016/j.biopha.2018.09.154> PMID: 30551461.
- [19] Huang H, Chen AY, Ye X, et al. Galangin, a flavonoid from lesser galangal, induced apoptosis via p53-dependent pathway in ovarian cancer cells. *Molecules* 2020;25(7):1579. <https://doi.org/10.3390/molecules25071579> PMID: 32235536.
- [20] Xuan H, Ou A, Hao S, et al. Galangin protects against symptoms of dextran sodium sulfate-induced acute colitis by activating autophagy and modulating the gut microbiota. *Nutrients* 2020;12(2):347. <https://doi.org/10.3390/nu12020347> PMID: 32013062.
- [21] Ma YL, Zhao F, Yin JT, et al. Two approaches for evaluating the effects of galangin on the activities and mRNA expression of seven CYP450. *Molecules* 2019;24(6):1171. <https://doi.org/10.3390/molecules24061171> PMID: 30934565.
- [22] Kalhotra P, Chittepu VCSR, Osorio-Revilla G, et al. Discovery of galangin as a potential DPP-4 inhibitor that improves insulin-stimulated skeletal muscle glucose uptake: a combinational therapy for diabetes. *Int J Mol Sci* 2019;20(5):1228. <https://doi.org/10.3390/ijms20051228> PMID: 30862104.
- [23] Patil S, Ujalambkar V, Rathore A, et al. Galangin loaded galactosylated pluronic F68 polymeric micelles for liver targeting. *Biomed Pharmacother* 2019;112. <https://doi.org/10.1016/j.biopha.2019.108691> PMID: 30798131.
- [24] Yang CC, Lin CC, Hsiao LD, et al. Galangin inhibits thrombin-induced MMP-9 expression in SK-N-SH cells via protein kinase-dependent NF- κ B phosphorylation. *Int J Mol Sci* 2018;19(12):4084. <https://doi.org/10.3390/ijms19124084> PMID: 30562971.
- [25] Sulaiman GM. Molecular structure and anti-proliferative effect of galangin in HCT-116 cells: in vitro study. *Food Sci Biotechnol* 2016;25(1):247–52. <https://doi.org/10.1007/s10068-016-0036-4> PMID: 30263264.
- [26] Kale VM, Namdeo A. Antiarthritic effect of galangin isolated from rhizomes of *Alpinia officinarum* in complete Freund's adjuvant-induced arthritis in rats. *Int J Pharm Pharm Sci* 2014;6:499–505.
- [27] Fu Q, Gao Y, Zhao H, et al. Galangin protects human rheumatoid arthritis fibroblastlike synoviocytes via suppression of the NF κ B/NLRP3 pathway. *Mol Med Rep* 2018;18:3619–24. <https://doi.org/10.3892/mmr.2018.9422> PMID: 30152847.
- [28] Muthuraman P, Mistry B, Enkhataivan G, et al. Efficacy of carnosine on activation of caspase 3 and human renal carcinoma cell inhibition. *Int J Biol Macromol* 2016;92:377–82. <https://doi.org/10.1016/j.jbiomac.2016.07.044> PMID: 27426703.
- [29] Borges CC, Estrela C, Lopes FC, et al. Effect of different diode laser wavelengths on root dentin decontamination infected with *Enterococcus faecalis*. *J Photochem Photobiol, B* 2017;176:1–8. <https://doi.org/10.1016/j.jphotobiol.2017.09.009> PMID: 28938202.
- [30] Zhuang Z, Ye G, Huang B. Kaempferol Alleviates the Interleukin-1 β -Induced Inflammation in Rat Osteoarthritis Chondrocytes via Suppression of NF- κ B. *Medical Science Monitor International Medical Journal of Experimental and Clinical Research*. 2017; 23:3925–3931. <https://doi.org/10.12659/MSM.902491> PMID: 28806392.
- [31] Oestergaard S, Chouinard L, Doyle N. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. *Osteoarthritis Cartilage* 2006;14:670–9. <https://doi.org/10.1016/j.joca.2006.01.004> PMID: 16500121.
- [32] Castrogiovanni P, Trovato FM, Loreto C, et al. Nutraceutical supplements in the management and prevention of osteoarthritis. *Int J Mol Sci* 2016;17(12):2042. <https://doi.org/10.3390/ijms17122042> PMID: 27929434.
- [33] Dimitra K, Athanasios M, Dimitrios PB, et al. The role of flavonoids in inhibiting Th17 responses in inflammatory arthritis. *J Immunol Res* 2018:9324357. <https://doi.org/10.1155/2018/9324357> PMID: 32189997.
- [34] Chow YY, Chin KY. The role of inflammation in the pathogenesis of osteoarthritis. *Mediators Inflamm* 2020;2020:8293921. <https://doi.org/10.1155/2020/8293921> PMID: 32189997.
- [35] Bauerova K, Bezek A. Role of reactive oxygen and nitrogen species in the etiopathogenesis of rheumatoid arthritis. *Gen Physiol Biophys* 1999;18:15–20. PMID: 10703714.
- [36] Heliövaara M, Knekt P, Aho K, et al. Serum antioxidants and risk of rheumatoid arthritis. *Ann Rheum Dis* 1994;53:51–3. <https://doi.org/10.1136/ard.53.1.51> PMID: 8311556.
- [37] Lobo V, Patil A, Phatak A, et al. Free radicals, antioxidants and functional foods: impact on human health. *Pharmacogn Rev* 2019;4:118–26. <https://doi.org/10.4103/0973-7847.70902> PMID: 22228951.
- [38] Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:1219–23. PMID: 15996055.
- [39] Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. *Arthritis Res* 2000;2:33–7. <https://doi.org/10.1186/ar67> PMID: 11094416.
- [40] Leyva-López N, Gutierrez-Grijalva EP, Ambríz-Pérez DL, et al. Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases. *Int J Mol Sci* 2016;17(6):921. <https://doi.org/10.3390/ijms17060921> PMID: 27294919.
- [41] Jun-Jiang L, Bin-Feng C, Yao-Xin G, et al. Protective effect of kaempferol, a flavonoid widely present in varieties of edible plants, on IL-1 β -induced inflammatory response via inhibiting MAPK, Akt, and NF- κ B signalling in SW982 cells. *J Funct Foods* 2016;27:214–22. <https://doi.org/10.1016/j.jff.2016.09.003>.
- [42] Lee H, Park Y, Ahn CW, et al. Deer bone extract suppresses articular cartilage damage induced by monosodium iodoacetate in osteoarthritis rats: an in vivo micro-computed tomography study. *J Med Food* 2014;17:701–6. <https://doi.org/10.1089/jmf.2013.2959> PMID: 24797662.
- [43] Guzman RE, Evans MG, Bove S, et al. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. *Toxicol Pathol* 2003;31:619–24. <https://doi.org/10.1080/01926230390241800> PMID: 14585729.
- [44] Amal AA, Veeramani C, Govindasamy C, et al. Galangin controls streptozotocin-caused glucose homeostasis and reverses glycolytic and gluconeogenic enzyme changes in rats. *Arch Physiol Biochem* 2020;126:101–6. <https://doi.org/10.1080/13813455.2018.1498521> PMID: 30269607.